21Jun/13

Novartis heart failure drug gets FDA incentives – Bioscience Technology


Economic Times

Novartis heart failure drug gets FDA incentives
Bioscience Technology
Novartis said patients treated with serelaxin in a late-stage trial were 37 percent less likely to die in the six months after a heart failure episode compared with patients who received standard treatment. The FDA created the breakthrough therapy …
FDA grants Breakthrough Therapy designation to Novartis’ serelaxin (RLX030 …FierceBiotech
US FDA deems Novartis’ heart failure candidate a ‘breakthrough’PMLiVE
Novartis Heart-Failure Drug Wins ‘Breakthrough’ Status at FDABusinessweek
Medical Daily –DailyFinance –TheHeart.Org
all 13 news articles »